Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02829944 · ClinicalTrials.gov registry record · Phase 4

Impact of Local Anesthetic Wound Infiltration on Postoperative Pain Following Cesarean Delivery

A Phase 4 study of Pain, sponsored by Duke University.

Completed
Registry status
Phase 4
Development phase
84
Enrollment target
1
Study location

NCT02829944 is a Phase 4 study of Pain that has completed, run by Duke University. The registered enrollment target is 84 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02829944, a Phase 4 study of Pain, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 4
Development phase
84 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if the infusion of the local anesthetic ropivacaine (a numbing medicine) and the non-steroidal anti-inflammatory drug ketorolac (a pain killer similar to ibuprofen) through a catheter placed along the cesarean delivery incision, will reduce the pain experienced after cesarean section and need for narcotic pain medicine.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Ketorolac
  • DRUG Ropivacaine

Study Locations (1)

North Carolina

  • Duke University Hospital - Durham

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2016-11
Est. Completion 2019-09
Phase Phase 4

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT02829944

The ClinicalTrials.gov registry entry for NCT02829944 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (72% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02829944 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT02829944 about?

NCT02829944 is a clinical study titled "Impact of Local Anesthetic Wound Infiltration on Postoperative Pain Following Cesarean Delivery". The purpose of this study is to determine if the infusion of the local anesthetic ropivacaine (a numbing medicine) and the non-steroidal anti-inflammatory drug ketorolac (a pain killer similar to ibuprofen) through a catheter placed along the cesarean delivery incision, will reduce the pain experien...

What is the current status of trial NCT02829944?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 84 participants. The study started on 2016-11. Estimated completion is 2019-09.

What conditions does trial NCT02829944 study?

This clinical trial studies the following conditions: Pain.

What interventions are being tested in trial NCT02829944?

The interventions under investigation include: Placebo (DRUG), Ketorolac (DRUG), Ropivacaine (DRUG).

Who is sponsoring clinical trial NCT02829944?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02829944 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.